Publication
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.
Authors not recorded
Mol Cancer2022PMID 34980131PMC8722280stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerLung Squamous Cell Carcinomacivic_curation1.00
- drugCamrelizumabcivic_curation1.00
- drugCarboplatin/Paclitaxel Regimencivic_curation1.00
- variantLow on-treatment bTMBcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 34980131
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Low on-treatment bTMB1 | ||||||||
| Camrelizumab + Carboplatin/Paclitaxel RegimenCombination | Lung Squamous Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID12919This is part of the randomised double-blind phase 3 trial, CameL-sq, a study that assessed the therapeutic effectiveness of the PD-1 blockade, camrelizumab plus chemotherapy as first-line treatment in… (full text at CIViC) PMID 34980131 · Jiang et al., 2022 · Open in CIViC | civic |